Clinical Trial Update: D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC [Phase 2, Phase 3]

View source ↗

Summary

A head-to-head Phase 2/Phase 3 trial compares D-0316 to icotinib in locally advanced or metastatic non-small cell lung cancer with EGFR-sensitizing mutations; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• D-0316
• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2, Phase 3 | Status: COMPLETED